Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of General Internal Medicine
Published in: Journal of General Internal Medicine 11/2014

01-11-2014 | Capsule Commentary

Capsule Commentary on Piller et al., Characteristics and Long-Term Follow-Up of Participants With Peripheral Vascular Disease During ALLHAT

Author: Stephen K. Williams, MD, MS

Published in: Journal of General Internal Medicine | Issue 11/2014

Login to get access

Excerpt

More than a decade ago, the ALLHAT trial1 influenced the Joint National Committee (JNC) 7 to recommend diuretics for initial anti-hypertensive therapy in patients without “compelling indications.”2 JNC 8 does not comment on specific high-risk conditions considered compelling indications, other than chronic kidney disease (CKD).3 However, there are other conditions generally considered compelling indications to start a specific anti-hypertensive class, including: heart failure, postmyocardial infarction status, high coronary heart disease risk, diabetes and prior stroke.2 …
Literature
1.
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive And Lipid-Lowering Treatment To Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981–2997.CrossRef
2.
Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560–2572.
3.
James PA, Oparil S, Carter BL, et al. Evidence-Based Guideline for the Management of High Blood Pressure in Adults:  Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507–20.
4.
Piller LB, Simpson LM, Baraniuk S, et al. Characteristics and Long-Term Follow-up of Participants with Peripheral Arterial Disease during ALLHAT. J Gen Intern Med. DOI: 10.1007/s11606-014-2947-1
Metadata
Title
Capsule Commentary on Piller et al., Characteristics and Long-Term Follow-Up of Participants With Peripheral Vascular Disease During ALLHAT
Author
Stephen K. Williams, MD, MS
Publication date
01-11-2014
Publisher
Springer US
Published in
Journal of General Internal Medicine / Issue 11/2014
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-014-2983-x

Other articles of this Issue 11/2014

Journal of General Internal Medicine 11/2014 Go to the issue

Original Research

Provider Collaboration: Cohesion, Constellations, and Shared Patients

Healing Arts

Up for Yes

Original Research

Innovation in the Safety Net: Integrating Community Health Centers Through Accountable Care

Original Research

Assessing the Impact of Nurse Post-Discharge Telephone Calls on 30-Day Hospital Readmission Rates

Original Research

Strategies Used by Older Adults with Asthma for Adherence to Inhaled Corticosteroids

Clinical Practice: Clinical Vignettes

Ciprofloxacin-Induced Tendinopathy of the Gluteal Tendons
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits